Clinical trials: Demyelinating Disease
Spinal Cord Injury, Cerebral Palsy
Experimental Evaluation of Wheelchair-Mounted Robotic Arms
Researchers from the University of South Florida's Rehabilitation Engineering program are looking for volunteers to participate in a research study for experimental evaluation of wheelchair-mounted robotic arms (WMRAs).
- Conditions
- Spinal Cord Injury, Cerebral Palsy, Multiple Sclerosis
- Trial name
- HRI (NCT01652352)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Multiple Sclerosis
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
- Trial name
- SUNBEAM (NCT02294058)
- Testing
- Ozanimod, Interferon beta-1a
- Where
- 224 sites in United States, Belarus and 23 more
- Volunteers
- 1,346 people
- Sponsor
- Celgene
Multiple Sclerosis
Resilience in Young Adults Newly Diagnosed With Multiple Sclerosis
This study aims to fill the gap of knowledge on the biopsychosocial (BPS) characteristics and resilience of young adults newly diagnosed with Multiple Sclerosis, to evaluate the relationship among these variables, and to develop…
- Trial name
- BPS-ARMS (NCT03825055)
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Universita di Verona
Multiple Sclerosis, Myasthenia Gravis
Serum Auto-Antibodies in Neurological Diseases
Under normal conditions our immune system protects us against infections and tumors. The immune system does this by recognizing that the infecting organism or the tumor is foreign to the body and attacking it.
- Conditions
- Multiple Sclerosis, Myasthenia Gravis, Transverse Myelitis
- Trial name
- SAA (NCT00704626)
- Testing
- Blood Draw, Cheek swab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Davis
Multiple Sclerosis
Bright Light Therapy for Sleep Disturbance in People With Multiple Sclerosis
Sleep disturbance is common in people with multiple sclerosis (MS) and contributes to diminished quality of life. Bright light therapy may be an innovative strategy to reduce sleep disturbance in MS, possibly through its effects…
- Trial name
- NCT04054050
- Testing
- Light therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Depression - Major Depressive Disorder
Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis
Canada has one of the highest rates of multiple sclerosis (MS). MS patients experience disabling motor, visual, and sensory symptoms, and a high risk of comorbid major depressive disorder (MDD) and severe fatigue.
- Conditions
- Multiple Sclerosis, Depression - Major Depressive Disorder, Fatigue
- Trial name
- NCT07562074
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Multiple Sclerosis
Intermittent Low Oxygen Breathing: A First Study Testing Different Disease Stages in People Living With MS
This study will look at the safety, tolerability and feasibility of a non-invasive treatment called Acute Intermittent Hypoxia (AIH) in people with Multiple Sclerosis (MS) at different stages of the disease course.
- Trial name
- LOxyMS (NCT07631143)
- Testing
- Acute Intermittent Hypoxia
- Volunteers
- 9 people
- Sponsor
- University of Saskatchewan
Multiple Sclerosis, Functional Neurological Disorders
Bridging Gaps in the Multidimensional Assessment and Management of Overlapping Symptoms in Multiple Sclerosis and Functional Motor Disorders: Prevalence and Rehabilitation Effectiveness
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that may cause a broad range of motor and non-motor symptoms.
- Trial name
- NCT07856485
- Testing
- Functional Motor Disorder-Specific Multidisciplinary Rehabilitation, Conventional Multiple Sclerosis Rehabilitation
- Where
- 2 sites in Italy
- Volunteers
- 192 people
- Sponsor
- IRCCS San Raffaele
Multiple Sclerosis, Relapsing-Remitting
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
B-cells have an important role in the pathogenesis of multiple sclerosis (MS). Ocrelizumab, a medication that targets B-cells have been found to be highly effective in stopping the disease activity in relapsing-remitting MS.
- Trial name
- NCT04261790
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
Depicting Neurogenic Dysphagia in Multiple Sclerosis Patients; Clinical and Endoscopic Studies
The purpose of this study is to evaluate neurogenic dysphagia in Multiple Sclerosis patients using dysphagia questionnaires and endoscopic study; and to correlate that to MS types, severity, duration, and imaging modalities
- Trial name
- NCT03552185
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Kasr El Aini Hospital
Multiple Sclerosis
Detection of Pattern of Some Unusual Signs and Symptoms of Multiple Sclerosis
Each Multiple Sclerosis patient will be submitted to Cognitive Abilities Screening Instrument (CASI), Expanded Disability Status Scale, Epowrth Sleeping Scale(ESS),Fatigue Severity Scale(FSS), Hamilton Depression Rating Scale…
- Trial name
- NCT04100343
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Multiple Sclerosis
Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI)
The aim of this study is to assess the efficacy of endovascular treatment (balloon angioplasty and/or stenting) for the improvement of clinical symptoms in multiple sclerosis patients.
- Trial name
- NCT01264848
- Testing
- balloon angioplasty and/or stenting
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Euromedic Specialist Clinics, Poland
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive
Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients
Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant.
- Trial name
- NCT04550650
- Testing
- Training groupe, PNF, Spinning grp
- Where
- Hungary
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital
Multiple Sclerosis
The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Walking, Balance, and Cognitive Functions in Individuals With Multiple Sclerosis
This interventional clinical trial aims to investigate the effects of internal and external focus-based exercise training combined with cognitive dual-task training in individuals diagnosed with multiple sclerosis.
- Trial name
- NCT07507084
- Testing
- Internal Focus Dual-Task Training, External Focus Dual-Task Training
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Kutahya Health Sciences University
Multiple Sclerosis, Relapsing-Remitting
Melatonin in Relapsing-Remitting Multiple Sclerosis Patients
The purpose of this study is to determine whether melatonin is effective in the treatment of relapsing-remitting multiple sclerosis patients as a supplement to the main disease-modifying drugs.
- Trial name
- NCT01279876
- Testing
- Melatonin
- Where
- Iran
- Volunteers
- 25 people
- Sponsor
- Tehran University of Medical Sciences
Relapsing Remitting Multiple Sclerosis
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
- Trial name
- NCT02258217
- Testing
- Acthar
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- OhioHealth
Thrombocytopenia, Metachromatic Leukodystrophy
Stem Cell Transplantation (SCT) for Genetic Diseases
OBJECTIVES: I. Ascertain whether stem cell transplantation (SCT) is an effective method by which missing or dysfunctional enzymes can be replaced in patients with various inborn errors of metabolism. II.
- Conditions
- Thrombocytopenia, Metachromatic Leukodystrophy, Fanconi's Anemia, Thalassemia Major
- Trial name
- NCT00004378
- Testing
- Stem Cell Transplantation
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost.
- Trial name
- DESIRE MS (NCT07189325)
- Testing
- Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT04155424
- Testing
- Eculizumab
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 5 people
- Sponsor
- Alexion Pharmaceuticals, Inc.